What about COVID-19 and arachidonic acid pathway?

Published in: European journal of clinical pharmacology (2020)

PGE2 levels and other PGs levels should be measured in patients with COVID-19. Lowering the PGE2 levels through inhibition of human microsomal prostaglandin E synthase-1 (mPGES-1) can enhance the host immune response against COVID-19. In addition, the hybrid compounds, such as COX-2 inhibitors/TP antagonists, can be an innovative treatment to control the overall balance between AA mediators in patients with COVID-19.

Keyphrases

coronavirus disease
sars cov
immune response
endothelial cells
toll like receptor
dendritic cells
combination therapy